Hematology

Emisphere reports results from phase III oral heparin trial

Published in Blood Weekly, June 20th, 2002

Emisphere Technologies, Inc., (EMIS), announced initial results from its phase III study with an oral heparin formulation for the prevention of deep vein thrombosis (DVT, or blood clots) in total hip replacement surgery patients.

The results did not demonstrate the superiority of oral heparin, when dosed in a 30-day treatment regimen, compared with Aventis' Lovenox (enoxaparin) administered by injection in a 10-day dosing regimen in preventing DVTs.

"The rigorous study design of PROTECT sought at least an absolute 10% reduction in DVT events, to claim clinical superiority to the FDA," said Russell Hull, MD, director of the Thrombosis Research Unit,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-06-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry